Market Cap (In SEK)
148.33 Million
Revenue (In SEK)
1.03 Million
Net Income (In SEK)
-64.88 Million
Avg. Volume
486.27 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.8-5.61
- PE
- -
- EPS
- -
- Beta Value
- 1.745
- ISIN
- SE0015658570
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Peter Selin
- Employee Count
- -
- Website
- https://www.kancera.com
- Ipo Date
- 2011-02-25
- Details
- Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
More Stocks
-
PSYGFPsyence Group Inc.
PSYGF
-
7590
-
RAINBOW
-
LPCK
-
6207
-
CCE
-
LYSCF
-
1718Mikikogyo Co., Ltd.
1718